Prostate cancer is a common cancer affecting the lives of millions of men worldwide.It is currently the most commonly diagnosed cancer for men other than skin cancer.The accuracy of the pathologic diagnosis of Prostate malignancy is critical for optimal patient care.Even though the diagnosis can usually be made on morphologic features, it is sometimes difficult to reach a firm diagnosis by routine histological study.There is no single morphologic feature which is cancer specific.Immunohistochemical (IHC) markers are often used as an aid in the diagnosis of prostatic adenocarcinoma.The loss of basal cells in prostate carcinoma is the most important diagnostic hallmark of malignancy.p63 staining is a sensitive and specific IHC marker for the identification of basal cells in diagnosing prostate specimens.Malignancy is strongly supported by absence of basal cell staining by IHC of p63 in a morphologically suspicious lesion.The use of negative staining for basal cell specific markers like p63 has several caveats.Many Benign mimics of prostate cancer may have a discontinuous basal cell layer.Due to these limitations,a sensitive and specific immunohistochemical marker that stains positively in prostatic adenocarcinoma would be of great value.Alpha-Methylacyl-CoA-Racemase (AMACR) is an IHC marker found to be consistently up regulated in prostate carcinoma..A cross sectional study was therefore undertaken to evaluate the role of immune-histochemistry in the proliferative lesions of prostate using p63 and AMACR antibodies.It was found that Immunohistochemical staining of AMACR and p63 are useful immunological markers to diagnose prostate carcinoma.